Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Delivering erythropoietin through genetically engineered cells.

D Bohl1, J M Heard

  • 1Retrovirus and Genetic Transfer Laboratory, CNRS ERS 572, Pasteur Institute, Paris, France. dbohl@pasteur.fr

Journal of the American Society of Nephrology : JASN
|November 7, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Human and Bovine Tuberculosis.

The Journal of comparative medicine and surgery·2022
Same author

The impact of COVID-19 on rare metabolic patients and healthcare providers: results from two MetabERN surveys.

Orphanet journal of rare diseases·2020
Same author

In situ retrovirus-mediated gene transfer into the liver.

Methods in molecular medicine·2014
Same author

Delivery of therapeutic proteins from genetically-modified cells.

Restorative neurology and neuroscience·2011
Same author

Astrocytic protection of spinal motor neurons but not cortical neurons against loss of Als2/alsin function.

Human molecular genetics·2009
Same author

longitudinal analysis of levels of immunoglobulins against BK virus capsid proteins in kidney transplant recipients.

Clinical and vaccine immunology : CVI·2008
Same journal

Variants to Functions to Therapeutic Strategies Toward Genomically Informed Care for Autosomal Dominant Polycystic Kidney Disease.

Journal of the American Society of Nephrology : JASN·2026
Same journal

Personalizing Cardio-Kidney-Metabolic Therapy: Closer But Not There Yet.

Journal of the American Society of Nephrology : JASN·2026
Same journal

Autosomal Dominant Tubulointerstitial Kidney Disease: My Kingdom for a Biomarker.

Journal of the American Society of Nephrology : JASN·2026
Same journal

Beyond the Margin: Improving Noninferiority Trials of Kidney Transplant Immunosuppression.

Journal of the American Society of Nephrology : JASN·2026
Same journal

Parathyroid Hormone Receptor 1 Facilitates Cyst Growth in Genetic Models of Autosomal Dominant Polycystic Kidney Disease.

Journal of the American Society of Nephrology : JASN·2026
Same journal

Alanyl-tRNA Synthetase 1 and Cyst Growth in Autosomal Dominant Polycystic Kidney Disease.

Journal of the American Society of Nephrology : JASN·2026
See all related articles

Gene transfer using adeno-associated vectors delivered erythropoietin (Epo) to treat beta-thalassemia in mice. This approach improved erythropoiesis by boosting fetal hemoglobin synthesis.

Area of Science:

  • Biotechnology and Genetic Engineering
  • Hematology
  • Molecular Medicine

Background:

  • Erythropoietin (Epo) is a glycoprotein hormone crucial for red blood cell production.
  • Pathological conditions like chronic renal failure and hemoglobinopathies can benefit from Epo administration.
  • Gene transfer offers a potential therapeutic strategy for diseases such as beta-thalassemia.

Purpose of the Study:

  • To develop a low-cost, low-risk gene therapy for conditions benefiting from Epo.
  • To investigate the efficacy of Epo gene transfer in a mouse model of beta-thalassemia.
  • To assess the potential of Epo to stimulate fetal hemoglobin synthesis.

Main Methods:

  • Development of retroviral and adeno-associated vectors expressing Epo cDNA.

Related Experiment Videos

  • Gene transfer into skeletal muscles.
  • Utilizing a tetracycline-regulated system to control Epo secretion and prevent polycythemia.
  • Intramuscular injection of an adeno-associated vector expressing Epo cDNA into beta-thalassemia mouse models.

    • Main Results:

    • Continuous Epo secretion was observed for at least one year post-injection.
    • Gene transfer improved erythropoiesis in the treated mice.
    • Increased synthesis of fetal hemoglobin was achieved, addressing the globin chain imbalance.

    Conclusions:

    • Adeno-associated vector-mediated Epo gene transfer is a viable strategy for treating beta-thalassemia.
    • Epo gene therapy can effectively enhance fetal hemoglobin production.
    • Controlled Epo secretion via gene transfer shows promise for managing hemoglobinopathies.